title: [Cardiovascular effects of incretin-based therapies].
abstract: Pharmacological modulation of the glucagon-like peptide-1 (GLP-1) system has emerged as a new therapeutic option for treatment of diabetes mellitus. In addition to the glucose lowering potential GLP-1 was found to have a variety of cardioprotective effects. GLP-1 reduced the size of myocardial infarction during acute ischemia by activation of prosurvival pathways including PI3-kinase, Akt und ERK1/2. In addition, GLP-1 prevented atherosclerotic lesion formation in experimental models and improved endothelial function while acting anti-inflammatory. Furthermore GLP-1 was found to improve chronic heart failure by increasing insulin independent cellular glucose transport. Consequently GLP-1 based therapies might reduce cardiovascular events in diabetic patients which is currently evaluated in clinical endpoint studies.
authors.affiliation: Medizinische Klinik I, Kardiologie, Pneumologie und Angiologie, Universitätsklinikum Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. mlehrke@ukaachen.de
authors.forename: M
authors.initials: M
authors.lastname: Lehrke
authors.forename: N
authors.initials: N
authors.lastname: Marx
mesh_terms: D002316:Cardiotonic Agents / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents; D007004:Hypoglycemic Agents; D054795:Incretins